Entasis and GARDP to evaluate zoliflodacin in Phase III trial for drug-resistant gonorrhea

US-based Entasis Therapeutics and the not-for-profit Global Antibiotic Research& Development Partnership (GARDP) have entered a partnership to develop a new treatment for drug-resistant gonorrhea.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news